CRDF

Cardiff Oncology, Inc. is a clinical-stage biotechnology company focused on developing novel therapies for various cancers through PLK1 inhibition. Its lead asset, onvansertib, is a PLK1 inhibitor being evaluated in combination with standard-of-care therapeutics for indications such as RAS-mutated metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, and triple negative breast cancer. The company's development strategy aims to target tumor vulnerabilities to enhance treatment efficacy.